European Monitoring Centre for Drugs and Drug Addiction. (2018) Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA; 5F-ADB) in the framework of the Council Decision on new psychoactive substances. Risk Assessments. Luxembourg: Publications Office of the European Union.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Risk assessment 5F-MDMB-PINACA)
- Published Version
735kB |
This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 5F-MDMB-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > International
Repository Staff Only: item control page